These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

220 related articles for article (PubMed ID: 29936676)

  • 1. How the Process of the CSR Activities Works on Private Hospitals and Pharmaceutical Firms: Multiple Case Study from Strategic Perspective.
    Yıldırım M; Dinçer MAM
    J Relig Health; 2020 Apr; 59(2):961-985. PubMed ID: 29936676
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Corporate social responsibility in global health: an exploratory study of multinational pharmaceutical firms.
    Droppert H; Bennett S
    Global Health; 2015 Apr; 11():15. PubMed ID: 25886175
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Corporate social responsibility to improve access to medicines: the case of Brazil.
    Thorsteinsdóttir H; Ovtcharenko N; Kohler JC
    Global Health; 2017 Feb; 13(1):10. PubMed ID: 28222793
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Understanding the dynamics of capital structure, corporate governance, and corporate social responsibility in high- and low-leveraged US and Chinese firms.
    Mahmood AN; Arslan HM; Younas ZI; Komal B; Ali K; Mubeen M
    Environ Sci Pollut Res Int; 2023 Apr; 30(16):46204-46221. PubMed ID: 36710308
    [TBL] [Abstract][Full Text] [Related]  

  • 5. How does social responsibility investment strategy contribute to hospitality firms' recovery from public health emergencies? The case of COVID-19 pandemic.
    Wu D; Li H; Yang J
    Int J Hosp Manag; 2023 Aug; 113():103530. PubMed ID: 37292494
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Corporate Social Responsibility in Family Firms: Status and Future Directions of a Research Field.
    Stock C; Pütz L; Schell S; Werner A
    J Bus Ethics; 2023 Mar; ():1-61. PubMed ID: 37359803
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Impact of Financial Redundancy on Corporate Social Responsibility Performance: Evidence From Chinese Listed Firms.
    He L; Gan S; Zhong T
    Front Psychol; 2022; 13():882731. PubMed ID: 35664182
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Corporate Social Responsibility Framework: An Innovative Solution to Social Determinants of Health in the USA.
    Jain P; Jain B; Dee EC
    J Racial Ethn Health Disparities; 2024 Feb; 11(1):7-22. PubMed ID: 36689122
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Moderating role of financial ratios in corporate social responsibility disclosure and firm value.
    Naseem MA; Lin J; Rehman RU; Ahmad MI; Ali R
    PLoS One; 2019; 14(4):e0215430. PubMed ID: 30998740
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evidence in Asian Food Industry: Intellectual Capital, Corporate Financial Performance, and Corporate Social Responsibility.
    Tsai CH; Mutuc EB
    Int J Environ Res Public Health; 2020 Jan; 17(2):. PubMed ID: 31968553
    [TBL] [Abstract][Full Text] [Related]  

  • 11. How High-Polluting Firms Suffer from Being Distracted form Intended Purpose: A Corporate Social Responsibility Perspective.
    Zhao XZ; Chen J; Chen FW; Wang W; Xia S
    Int J Environ Res Public Health; 2020 Dec; 17(24):. PubMed ID: 33317027
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Transparency in relations between multinational R&D pharmaceutical companies' corporate social responsibility activities and patient organizations in the Europe, Japan, and the United States].
    Kato M; Ishikawa H; Okuhara T; Kiuchi T
    Nihon Koshu Eisei Zasshi; 2019; 66(12):746-755. PubMed ID: 31875625
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Public health and corporate social responsibility: exploratory study on pharmaceutical companies in an emerging market.
    Dănescu T; Popa MA
    Global Health; 2020 Dec; 16(1):117. PubMed ID: 33302949
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Public preferences for corporate social responsibility activities in the pharmaceutical industry: Empirical evidence from Korea.
    Lee H; Kim SY; Kim G; Kang HY
    PLoS One; 2019; 14(8):e0221321. PubMed ID: 31430330
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The impact of hotel CSR for strategic philanthropy on booking behavior and hotel performance during the COVID-19 pandemic.
    Shin H; Sharma A; Nicolau JL; Kang J
    Tour Manag; 2021 Aug; 85():104322. PubMed ID: 34815613
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The philanthropic response of substantive and symbolic corporate social responsibility strategies to COVID-19 crisis: Evidence from China.
    Zhong M; Zhao W; Shahab Y
    Corp Soc Responsib Environ Manag; 2022 Mar; 29(2):339-355. PubMed ID: 35465450
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Corporate Social Responsibility programs of Big Food in Australia: a content analysis of industry documents.
    Richards Z; Thomas SL; Randle M; Pettigrew S
    Aust N Z J Public Health; 2015 Dec; 39(6):550-6. PubMed ID: 26259972
    [TBL] [Abstract][Full Text] [Related]  

  • 18.
    Fernandez-Muiños M; Money K; Saraeva A; Garnelo-Gomez I; Vazquez-Suarez L
    Heliyon; 2022 Nov; 8(11):e11930. PubMed ID: 36468134
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Assessing the Effect of Board Gender Diversity on CSR Reporting Through Moderating Role of Political Connections in Chinese Listed Firms.
    Shaheen R; Yang H; Bhutto MY; Bala H; Khan FN
    Front Psychol; 2021; 12():796470. PubMed ID: 35035372
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Engineering Students' Views of Corporate Social Responsibility: A Case Study from Petroleum Engineering.
    Smith JM; McClelland CJ; Smith NM
    Sci Eng Ethics; 2017 Dec; 23(6):1775-1790. PubMed ID: 28000093
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.